Oleic acid liquid
An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Oleic acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(6)
Multiple sclerosis in adults: management (NG220)
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
Brain tumours (primary) and brain metastases in over 16s (NG99)
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
Type 2 diabetes in adults: management (NG28)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 13 · Randomised trials: 1 · 1925–2026
Showing the 50 most relevant studies, sorted by most relevant.
Hua J, Hu M, Wang Y, et al.
2026
BackgroundOleic acid, a monounsaturated fatty acid (MUFA), exhibits beneficial properties in healthy subjects. However, it remains unclear whether these favorable effects extend to metabolically unhealthy individuals. Therefore, this study aimed to investigate the effect of an oleic acid-enriched oil formula on metabolic health outcomes.MethodsOur comprehensive systematic search was conducted in the following databases: PubMed, Scopus, Web of Science, and Google Scholar based on PRISMA guideline. The random-effect model was used to pool standardized mean differences (SMD).ResultsFifteen eligible studies met our inclusion criteria and were included in our systematic review and meta-analysis. Data analysis indicated that oleic acid consumption is not associated with improvement of lipid markers including total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), and triglyceride (TG). In addition, it has been shown that subgroup analysis based on the BMI of participants, intervention duration, and oleic acid content could not modify the response to oleic acid intervention in term of lipid profile. Moreover, combined effect of studies evaluating the effect of the oleic acid on the glycemic control, obesity measures, and blood pressure illustrated that oleic acid is not potent enough to affect them in unhealthy individuals.ConclusionThe current meta-analysis indicated that oleic acid intervention exerts population specific responses; despite its beneficial properties, oleic acid does not improve health outcomes in metabolically unhealthy individuals.
Abstract licence: CC BY
Xu H, Xu X, Sohouli MH
2026
Zou X, Liu H
2025
Zhu M, Zhang X, Zhang J, et al.
2026
Abou-Rjeileh U, Gouveia K, Lock AL, et al.
2025
- Oleic Acid
- Milk
- Cattle
Dairy cows going through the transition period experience a state of negative energy balance, driven by a mismatch between rising energy needs and reduced feed intake. Although fat breakdown (i.e., lipolysis) is a necessary adaptation to meet rising energy demands, excessive and prolonged lipolysis can increase disease risk. One strategy to mitigate this gap in energy is by increasing the energy density of the diet through fatty acid (FA) supplementation. Among available FA, oleic acid (OA) has gained attention not only as an energy source, but also for its broader biological effects. This review examines the role of OA in dairy cow metabolism, extending beyond its caloric contribution to its regulatory influence on lipid metabolism, insulin signaling, oxidative stress, and inflammation. We summarize findings from both ruminants and nonruminants to provide mechanistic insights into how OA modulates cellular pathways and contributes to metabolic adaptations, especially within adipose tissue during periods of physiological stress. Additionally, we highlight the nutritional implications of OA on production outcomes such as milk yield and composition, as well as its effects on adipose tissue. By integrating nutritional and mechanistic perspectives, this review provides a comprehensive evaluation of OA potential as a functional nutrient to support health and performance in transition dairy cows.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
7 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
15.6 hours
[L2896]
…
Half-life
Protein binding
[L2896]
Volume of distribution
[L2896]
…
Metabolism
Elimination
10%
[L2896]
…
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L2896]
Dermal LD50 in guinea pig was >3000 mg/kg .
[L2896]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L2896]
Fatty acids taken up by tissues are then stored in the form of triglycerides or oxidized .
[L2896]
Oleic acid was shown to penetrate rat skin .
[L2896]
Following oral administration of Brucea javanica oil emulsion in rats, the time of oleic acid to reach peak plasma concentration was approximately 15.6 hours .
[A33178]
[L2896]
[L2896]
Oleic acid is primarily transported via the lymphatic system .
[L2896]
[L2896]
[L2896]
Proteins and enzymes this drug interacts with in the body
PMID:25732850
Binds cholesterol .
PMID:25732850
Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport (By similarity)
Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids.
Functions as a transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2
PMID:35675826
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes.
Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand
PMID:10874028 PMID:11162439 PMID:11915042 PMID:37478846
Forms homo- or heterodimers with retinoic acid receptors (RARs) and binds to target response elements in response to their ligands, all-trans or 9-cis retinoic acid, to regulate gene expression in various biological processes .
PMID:10195690 PMID:11162439 PMID:11915042 PMID:16107141 PMID:17761950 PMID:18800767 PMID:19167885 PMID:28167758 PMID:37478846
The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 to regulate transcription .
PMID:10195690 PMID:11162439 PMID:11915042 PMID:17761950 PMID:28167758
The high affinity ligand for retinoid X receptors (RXRs) is 9-cis retinoic acid .
PMID:1310260
In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression .
PMID:20215566
On ligand binding, the corepressors dissociate from the receptors and coactivators are recruited leading to transcriptional activation .
PMID:20215566 PMID:37478846 PMID:9267036
Serves as a common heterodimeric partner for a number of nuclear receptors, such as RARA, RARB and PPARA .
PMID:10195690 PMID:11915042 PMID:28167758 PMID:29021580
The RXRA/RARB heterodimer can act as a transcriptional repressor or transcriptional activator, depending on the RARE DNA element context .
PMID:29021580
The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes .
PMID:10195690
Together with RARA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells .
PMID:28167758
Acts as an enhancer of RARA binding to RARE DNA element .
PMID:28167758
May facilitate the nuclear import of heterodimerization partners such as VDR and NR4A1 .
PMID:12145331 PMID:15509776
Promotes myelin debris phagocytosis and remyelination by macrophages .
PMID:26463675
Plays a role in the attenuation of the innate immune system in response to viral infections, possibly by negatively regulating the transcription of antiviral genes such as type I IFN genes .
PMID:25417649
Involved in the regulation of calcium signaling by repressing ITPR2 gene expression, thereby controlling cellular senescence PMID:30216632
Proteins that carry this drug through the body
PMID:25732850
Binds cholesterol .
PMID:25732850
Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport (By similarity)
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Oleic Acid
Matched from: Oleic acid
Additional database identifiers
Drugs Product Database (DPD)
6910
ChemSpider
553123
BindingDB
50250904
PDB
ELA
ZINC
ZINC000008217338
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3555
GeneCards
FABP1
GenBank Gene Database
M10617
GenBank Protein Database
182358
UniProt Accession
FABPL_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3559
GenAtlas
FABP4
GeneCards
FABP4
GenBank Gene Database
J02874
GenBank Protein Database
178347
Guide to Pharmacology
2534
UniProt Accession
FABP4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9232
GenAtlas
PPARA
GeneCards
PPARA
GenBank Gene Database
L02932
GenBank Protein Database
307341
Guide to Pharmacology
593
UniProt Accession
PPARA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9235
GenAtlas
PPARD
GeneCards
PPARD
GenBank Gene Database
L07592
GenBank Protein Database
190230
Guide to Pharmacology
594
UniProt Accession
PPARD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10477
GenAtlas
RXRA
GeneCards
RXRA
GenBank Gene Database
X52773
GenBank Protein Database
35885
Guide to Pharmacology
610
UniProt Accession
RXRA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9236
GenAtlas
PPARG
GeneCards
PPARG
GenBank Gene Database
U79012
GenBank Protein Database
1711117
Guide to Pharmacology
595
UniProt Accession
PPARG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9117
GeneCards
PMP2
GenBank Gene Database
X62167
GenBank Protein Database
35186
UniProt Accession
MYP2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3557
GenAtlas
FABP3
GeneCards
FABP3
GenBank Gene Database
X56549
GenBank Protein Database
31293
Guide to Pharmacology
2533
UniProt Accession
FABPH_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3555
GeneCards
FABP1
GenBank Gene Database
M10617
GenBank Protein Database
182358
UniProt Accession
FABPL_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4187
GenAtlas
GC
GeneCards
GC
GenBank Gene Database
L10641
GenBank Protein Database
639896
UniProt Accession
VTDB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3562
GenAtlas
FABP7
GeneCards
FABP7
GenBank Gene Database
AJ002962
GenBank Protein Database
2632065
UniProt Accession
FABP7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3559
GenAtlas
FABP4
GeneCards
FABP4
GenBank Gene Database
J02874
GenBank Protein Database
178347
Guide to Pharmacology
2534
UniProt Accession
FABP4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72